NASDAQ$ZLAB
Zai Lab Limited-ADR · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Zai Lab reported strong growth and execution in all areas of the business, expanded its portfolio of assets, and achieved regulatory milestones.
Zai Lab reported strong financial results for the year ended December 31, 2021. The company expanded its portfolio of potential first-in-class and/or best-in-class assets and made meaningful advances with its global pipeline. Commercial execution is gaining strong momentum for marketed products, including ZEJULA's inclusion in the NRDL for first-line ovarian cancer maintenance treatment.
- Expanded portfolio with potential first-in-class and/or best-in-class assets.
- Advanced global pipeline of 11 assets, including proof of concept for ZL-1102.
- Deepened gastric and lung cancer franchises with four additional drug candidates.
- Achieved additional regulatory submissions and approvals, including first non-oncology approval with NUZYRA®.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$44.2M
Revenue by segment
Zai Lab · $52M total across 3 segments · Q3 2023
- ZEJULA$41.6M+6.1%80.0%
- NUZYRA$5.5M+266.7%10.6%
- VYVGART franchise$4.9M—9.4%
Forward guidance
Zai Lab has set strategic priorities for 2022, including expediting medicines to patients, investing in R&D, and leveraging its position in China to accelerate revenue growth and source innovation.
Tailwinds
- Expedite bringing medicines to patients by accelerating data readouts and regulatory filings.
- File the NDA for efgartigimod in China in mid-2022.
- Initiate a registrational study in China for bemarituzumab in first-line advanced gastric and GEJ cancer.
- Move ZL-1102 into full global development and submit up to two INDs for compounds with global rights in 2022.
- Accelerate growing revenue base and source innovation internally and externally.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro